INARI MEDICAL
COMPANY PROFILE - August 2022
Extracting large clots from large vessels without the need for thrombolytics or ICU stay
Inari Medical is committed to treating and transforming the lives of patients suffering from venous diseases through pioneering devices specifically designed and purpose-built for the venous anatomy and its unique clot morphology
CURRENT MARKETS AND PRODUCTS
Offering highly differentiated products in the venous space, treating Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
PULMONARY EMBOLISM (PE)
THE CHALLENGE:
- When part of a blood clot travels to the lungs causing a blockage
- 3rd leading cause of cardiovascular death1
- Up to 15% 30-day all cause mortality2,3, 28% for high-risk PE2
- Up to 50% of PE patients have residual vascular obstrubiton4-6, and long-term complications are common7
THE INARI SOLUTION:
The FlowTriever® System
- A large bore catheter-based aspiration and mechanical thrombectomy system de- signed to remove large clots from large venous vessels, the right heart, pulmonary arteries and the lungs
- In May of 2018, the FlowTriever System received FDA approved labeling, making it the first mechanical thrombectomy device indicated for the treatment of Pulmo- nary Embolism (PE)
-
In January of 2021, FlowTriever received 510(k) market clearance from the U.S.
FDA for Right Atrial Clot in Transit becoming the first thrombectomy system not requiring a cardiopulmonary bypass circuit for blood clots in the right atrium
DEEP VEIN THROMBOSIS (DVT)
THE CHALLENGE:
- Blood clots that form in a deep vein, usually in the lower leg, thigh, or pelvis.
- Up to 50% of patients are expected to develop post-thrombotic syndrome (PTS)8
- Nearly 90% of PTS patients are unable to work 10 years after diagnosis9
- >10% of PTS patients develop venous leg ulcers10
THE INARI SOLUTION:
The ClotTriever® System
- Designed to core, capture and remove large clots from large venous vessels
- In February of 2017, the ClotTriever System received 510(k) market clearance from the U.S. FDA for the non-surgical removal of thrombi and emboli from the peripheral vasculature
FINANCIAL PROFILE
Robust quarterly revenue growth with gross margins of >80%
REVENUES | $92.7 |
$86.8 | |
(LAST 8 QUARTERS, $ IN MILLIONS) | $83.2 |
$72.9
$63.5
$57.4
$48.6
$38.7
Q3-20 | Q4-20 | Q1-21 | Q2-21 | Q3-21 | Q4-21 | Q1-22 | Q2-22 |
- "Pulmonary Embolism in 2017: Increasing Options for Increasing Incidence", National Center for Biotechnology Information, May 2017.
- PERT Consortium® Registry Data. Interim results on 5,048 Patients presented at PERT Symposium October 2021
- Schultz J, et al. Pulm Circ. 2019 Jan 11;9(3):2045894018824563;
- Chopard et al. 2017. Ame J of Cardiol. Volume 119, Issue 11, 1883-1889
- Miniati et al. 2006 Medicine. 85. 253-62. 10.1097/01.md.0000236952.87590.c8
- Mrozek et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 162(2):121-126. doi: 10.5507/bp.2018.001
- Sista AK, et al. Vasc Med. 2017 Feb;22(1):37-43
- Kahn, Susan R. Hematology Am Soc Hematol Educ Program. 2016 Dec 2; 2016(1): 413-418
- Kahn, et al. Arch Intern Med. 2004;164:17-26
- Galanaud, et al. Thromb Haemost 2018; 118(02): 320-328
FAST FACTS
PATIENT-FOCUSED
Pursuing extraordinary outcomes and improving the quality of life for patients since 2011
PRODUCT SIMPLICITY
Intuitive, easy-to-use,single-use devices that do not require capital equipment or the use of thrombolytic drugs
COMPELLING PROCEDURE ECONOMICS Products designed for short, single sessions, eliminating the need for expensive thrombolytics which require costly ICU stays and carry risks of major bleeding
COMMITMENT TO CLINICAL DATA Significant investment into real-worldand broad evidence generation to drive adoption; studies and registries include FLARE, CLOUT, FLASH, FLAME, and PEERLESS
SCALING COMMERCIAL ORGANIZATION Rapidly growing US sales team designed to help hospitals develop programs that systematically identify, triage and treat PE and DVT patients; international expansion commencing in Europe, Asia and Latin America
MARKET OPPORTUNITY | |
Combined addressable market of $5.8B in the US | |
alone, plus significant international opportunity | |
IPO | |
MARQUEE MED TECH IPO | |
1st non-biotech IPO post COVID-19 outbreak, | |
completed May, 2020 |
(NASDAQ: NARI)
CONTACT INFORMATION
6001 Oak Canyon, Ste #100 Irvine, CA 92618, U.S
Steinenbachgaesslein 49, 4051 Basel, Switzerland
info@inarimedical.com
inarimedical.com
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Inari Medical Inc. published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 16:07:07 UTC.